We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+4.89%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$189M
AUM Growth
-$1.06M
Cap. Flow
-$5.94M
Cap. Flow %
-3.14%
Top 10 Hldgs %
89.07%
Holding
42
New
4
Increased
5
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
CFRX
ContraFect Corporation
CFRX
+$2.31M
2
HNSN
HANSEN MEDICAL, INC. COM NEW
HNSN
+$2.15M
3
COLL icon
Collegium Pharmaceutical
COLL
+$1.36M
4
ADXS
Advaxis Inc
ADXS
+$750K
5
YTEN
Yield10 Bioscience, Inc. Common Stock
YTEN
+$617K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$12.3M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$902K
3
XNCR icon
Xencor
XNCR
+$643K
4
BIIB icon
Biogen
BIIB
+$161K
5
TTHI
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
+$35K

Sector Composition

Rank Sector Weight
1 Healthcare 85.81%
2 Consumer Staples 4.04%
3 Energy 3.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$84.8M 44.79%
732,553
-107,610
-13% -$12.3M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$53.4M 28.19%
206,756
– –
YTEN
3
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$7.64M 4.04%
236
+15
+7% +$617K
VRML
4
DELISTED
Vermillion, Inc.
VRML
$5.63M 2.97%
2,717,514
– –
HNSN
5
DELISTED
HANSEN MEDICAL, INC. COM NEW
HNSN
$4.83M 2.55%
528,144
+236,051
+81% +$2.15M
EQT icon
6
EQT Corp
EQT
$31B
$3.36M 1.77%
75,868
– –
MDVN
7
DELISTED
MEDIVATION, INC.
MDVN
$2.48M 1.31%
43,360
– –
SWN
8
DELISTED
Southwestern Energy Company
SWN
$2.19M 1.16%
96,483
– –
GILD icon
9
Gilead Sciences
GILD
$167B
$2.19M 1.15%
18,670
– –
CFRX
10
DELISTED
ContraFect Corporation
CFRX
$2.15M 1.14%
+569
New +$2.31M
BIOL
11
DELISTED
Biolase, Inc.
BIOL
$2.06M 1.09%
95
– –
MASI
12
DELISTED
Masimo
MASI
$1.42M 0.75%
36,600
– –
COLL icon
13
Collegium Pharmaceutical
COLL
$1.17B
$1.41M 0.74%
+78,768
New +$1.36M
CLR
14
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$1.39M 0.73%
32,674
– –
OMED
15
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$1.32M 0.7%
58,689
+14,000
+31% +$345K
OVV icon
16
Ovintiv
OVV
$16.2B
$896K 0.47%
16,260
+2,320
+17% +$148K
QDEL icon
17
QuidelOrtho
QDEL
$1.19B
$894K 0.47%
38,975
– –
AEGR
18
DELISTED
Aegerion Pharmaceuticals
AEGR
$873K 0.46%
46,000
– –
MRK icon
19
Merck
MRK
$315B
$854K 0.45%
15,720
– –
PTCT icon
20
PTC Therapeutics
PTCT
$6.52B
$813K 0.43%
16,900
– –
ARAY icon
21
Accuray
ARAY
$30.8M
$811K 0.43%
120,300
– –
TRNX
22
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$750K 0.4%
30,000
– –
RPTP
23
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$726K 0.38%
46,000
+16,000
+53% +$194K
ADXS
24
DELISTED
Advaxis Inc
ADXS
$724K 0.38%
+2,373
New +$750K
CTRA
25
DELISTED
Coterra Energy
CTRA
$662K 0.35%
21,000
– –
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Birchview Capital held 42 positions worth $189M, down 0.56% from $190M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Birchview Capital withdrew a net $5.94M in Q2 2015, closing 1 position and reducing 4 holdings. Its most notable exit was AUSPEX PHARMACEUTICALS INC COM STK (DE), an estimated $902K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier, followed by Consumer Staples and Energy.

Against the trend, Birchview Capital opened a new position in ContraFect Corporation worth $2.15M.

  • Birchview Capital's largest Q2 2015 buy was ContraFect Corporation: 569 shares worth $2.15M.
  • Birchview Capital added most to HANSEN MEDICAL, INC. COM NEW in Q2 2015, an estimated $2.15M increase.
  • Birchview Capital's biggest Q2 2015 reduction was Celgene Corp, cutting an estimated $12.3M.
  • Birchview Capital fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $902K.
  • Birchview Capital's ten largest holdings make up 89% of its $189M portfolio in Q2 2015.
  • Birchview Capital opened 4 new positions and closed 1 in Q2 2015.
  • Birchview Capital's portfolio value fell 0.56% quarter-over-quarter to $189M.

Based on Birchview Capital's 13F filing for Q2 2015, filed 13 Aug 2015.